- Report
- November 2024
- 100 Pages
Global
From €5619EUR$5,950USD£4,782GBP
- Report
- February 2025
- 200 Pages
Global
From €4240EUR$4,490USD£3,608GBP
- Report
- November 2024
- 150 Pages
Global
From €4580EUR$4,850USD£3,898GBP
- Report
- July 2024
- 231 Pages
Global
From €7508EUR$7,950USD£6,389GBP
- Report
- May 2024
- 200 Pages
Global
From €3919EUR$4,150USD£3,335GBP
- Report
- May 2022
- 196 Pages
Global
From €2479EUR$2,625USD£2,110GBP
€4958EUR$5,250USD£4,219GBP
- Report
- October 2022
- 270 Pages
Global
From €3541EUR$3,750USD£3,014GBP
- Report
- February 2024
- 250 Pages
Global
From €4722EUR$5,000USD£4,018GBP
- Report
- February 2024
- 250 Pages
Global
From €4722EUR$5,000USD£4,018GBP
- Report
- May 2021
- 50 Pages
China
From €2455EUR$2,600USD£2,090GBP
- Report
- August 2022
- 118 Pages
Global
From €4250EUR$4,500USD£3,616GBP
- Report
- September 2021
- 111 Pages
Global
From €4250EUR$4,500USD£3,616GBP
- Report
- November 2023
- 30 Pages
Global
From €3069EUR$3,250USD£2,612GBP
- Report
- August 2023
- 295 Pages
Global
From €8972EUR$9,500USD£7,635GBP
- Report
- February 2022
- 210 Pages
Global
From €7083EUR$7,500USD£6,027GBP
- Drug Pipelines
- January 2023
- 30 Pages
Global
From €2597EUR$2,750USD£2,210GBP
- Report
- August 2022
- 111 Pages
Global
From €4486EUR$4,750USD£3,817GBP
- Report
- June 2022
- 120 Pages
Global
From €4486EUR$4,750USD£3,817GBP
- Report
- April 2024
- 190 Pages
Global
From €4250EUR$4,500USD£3,616GBP
- Report
- April 2022
- 188 Pages
Global
From €3400EUR$3,600USD£2,893GBP

Golimumab is a biologic drug used to treat immune disorders such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis. It is a monoclonal antibody that works by blocking the action of tumor necrosis factor (TNF), a protein that plays a role in inflammation. Golimumab is administered as an intravenous infusion or subcutaneous injection.
Golimumab is one of several drugs used to treat immune disorders. Other drugs used to treat these conditions include biologics such as adalimumab, etanercept, and infliximab, as well as non-biologic drugs such as methotrexate and corticosteroids.
Golimumab is marketed by Janssen Biotech, Inc., a subsidiary of Johnson & Johnson. Other companies in the market include AbbVie, Amgen, and Pfizer. Show Less Read more